var data={"title":"IncobotulinumtoxinA (Xeomin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">IncobotulinumtoxinA (Xeomin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/426290?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=incobotulinumtoxina-xeomin-patient-drug-information\" class=\"drug drug_patient\">see &quot;IncobotulinumtoxinA (Xeomin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826166\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Distant spread of toxin effects:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing reports indicate that the effects of incobotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10894929\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xeomin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Xeomin;</li>\n      <li>Xeomin Cosmetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493109\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Neuromuscular Blocker Agent, Toxin;</li>\n      <li>\n        Ophthalmic Agent, Toxin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827173\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blepharospasm:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Initial: Total dose should be the same as previously administered onabotulinumtoxinA dose. If prior onabotulinumtoxinA dose is not known: 1.25 to 2.5 units/injection site (maximum initial dose: 35 units/eye or 70 units/both eyes). Number and location of injection sites based on disease severity and previous dose/response to onabotulinumtoxinA (in clinical trials, a mean number of 6 injections per eye were administered). Cumulative dose should not exceed 35 units/eye or 70 units/both eyes administered no more frequently than every 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Initial: 1.25 to 2.5 units/injection site (maximum initial dose: 25 units/eye for treatment-na&iuml;ve patients; 35 units/eye for patients previously receiving unknown dose). Titrate dose and interval for maximum patient benefit. Total dose should not exceed 100 units per treatment session. Administer no more frequently than every 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia: </b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Initial total dose: 120 units (in clinical trials, similar efficacy was noted with initial total doses of 120 and 240 units and between treatment experienced and treatment na&iuml;ve patients). Dose and number of injection sites should be individualized based on prior treatment, response, duration of effect, adverse events, number/location of muscle(s) to be treated and disease severity. In clinical trials most patients received a total of 2 to 10 injections into treated muscles. Administer no more frequently than every 3 months. Maximum cumulative dose per treatment session: 400 units.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Usual total dose does not exceed 200 units (maximum: 300 units; maximum dose per injection site: 50 units); administer no more frequently than every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reduction of glabellar lines:</b> IM: Inject 4 units into each of the 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle) for a total dose of 20 units per treatment session.  Administer no more frequently than every 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper limb spasticity:</b>  IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Initiate dosing at the low end of the dosing range and titrate as clinically indicated. Base dosage, frequency and number of injection sites on size, number and location of muscles to be treated, severity of spasticity, presence of local muscle weakness, patient&rsquo;s response to previous treatment and adverse event history. Administer no more frequently than every 3 months. Maximum cumulative dose per treatment session: 400 units.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clenched fist: Flexor digitorum superficialis or flexor digitorum profundus: 25 to 100 units divided into 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexed wrist:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\"> Flexor carpi radialis: 25 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor carpi ulnaris: 20 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexed elbow:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Brachioradialis: 25 to 100 units divided into 1 to 3 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Biceps: 50 to 200 units divided into 1 to 4 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Brachialis: 25 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pronated forearm:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pronator quadratus: 10 to 50 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pronator teres: 25 to 75 units divided into 1 to 2 injections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Thumb-in-palm:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor pollicis longus: 10 to 50 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adductor pollicis: 5 to 30 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor pollicis brevis/opponens pollicis: 5 to 30 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Initiate dosing at the low end of the dosing range and titrate as clinically indicated. Administer no more frequently than every 3 months. Total dose should not exceed 400 units in a treatment session.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexed wrist: Total initial dose 90 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor carpi radialis: Initial dose 50 units; subsequent dose range 25 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor carpi ulnaris: Initial dose 40 units; subsequent dose range 20 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clenched fist: Total initial dose 80 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor digitorum superficialis: Initial dose 40 units; subsequent dose range 40 to 100 units divided into 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor digitorum profundus: Initial dose 40 units; subsequent dose range 40 to 100 units divided into 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexed elbow: Total initial dose 130 to 190 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Brachioradialis: Initial dose 60 units; subsequent dose range 25 to 100 units divided into 1 to 3 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Biceps: Initial dose 80 units; subsequent dose range 75 to 200 units divided into 1 to 4 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Brachialis: Initial dose 50 units; subsequent dose range 25 to 100 units divided into 1 to 2 injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pronated forearm: Total initial dose 25 to 65 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pronator quadratus: Initial dose 25 units; subsequent dose range 10 to 50 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pronator teres: Initial dose 40 units; subsequent dose range 25 to 75 units divided into 1 to 2 injections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Thumb-in-palm: Total initial dose 10 to 40 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor pollicis longus: Initial dose 20 units; subsequent dose range 10 to 50 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adductor pollicis: Initial dose 10 units; subsequent dose range 5 to 30 units in 1 injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor pollicis brevis/opponens pollicis: Initial dose 10 units; subsequent dose range 5 to 30 units in 1 injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827175\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Initiate therapy at lowest recommended dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827171\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827170\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10894930\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xeomin: 50 units (1 ea); 100 units (1 ea); 200 units (1 ea) [latex free; contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826169\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16124978\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Xeomin Cosmetic: 100 units [contains albumin (human), sucrose 4.7 mg]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826167\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;\">An FDA-approved patient medication guide, which is available at  <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM222360.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68uEf/c3oG6DFfnJIB9VSi3w==&amp;TOPIC_ID=15586\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM222360.pdf</a> must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827176\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">For IM injection only. <b>Note:</b> Do not inject through pen marks (if proposed injection sites are marked with a pen); permanent tattooing effect may occur. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blepharospasm: Use a 30-gauge (12.5 mm length) needle. Electromyography guidance is unnecessary. Avoid injecting near the levator palpebrae superioris (may decrease ptosis). Avoid medial lower lid injections (may decrease ectropion). Apply pressure at the injection site to prevent ecchymosis in the soft eyelid tissues. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cervical dystonia and upper limb spasticity: Use a 26-gauge (37 mm length) needle for superficial muscles and a 22-gauge (75 mm length) needle for deeper musculature; electromyography or nerve stimulation may help localize the involved muscles. The Canadian labeling recommends avoiding administering bilateral injections or doses &gt;100 units to the sternocleidomastoid muscle (increased risk of adverse events, particularly dysphagia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reduction of glabellar lines: Use a 30- to 33-gauge (13 mm length) needle.  To reduce ptosis, corrugator injections should be &ge;1 cm above the bony supraorbital ridge and injections near the levator palpebrae superioris should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493111\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blepharospasm:</b> Treatment of adults with blepharospasm in patients previously treated with onabotulinumtoxinA (Botox).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cervical dystonia:</b> Treatment of adults with cervical dystonia in both botulinum toxin-na&iuml;ve and previously treated patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glabellar lines:</b> Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Upper limb spasticity:</b> Treatment of upper limb spasticity in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Xeomin: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <b>Cervical dystonia:</b> Treatment of cervical dystonia (spasmodic torticollis) in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <b>Hypertonicity disorders:</b> Treatment of hypertonicity disorders of the seventh nerve (eg, blepharospasm, hemifacial spasm) in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <b>Upper limb spasticity:</b> Treatment of poststroke spasticity of upper limb(s) in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Xeomin Cosmetic: <b>Glabellar lines:</b> Temporary improvement in the appearance of moderate to severe glabellar lines in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26341089\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Sialorrhea (drooling) (adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493106\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Botulinum products are not interchangeable; potency differences may exist between the products.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826360\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper limb spasticity and cervical dystonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Myasthenia (cervical dystonia: 7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Dysphagia (cervical dystonia: 13% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Neck pain (cervical dystonia: 7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Seizure (upper limb spasticity: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Xerostomia (upper limb spasticity: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Pain at injection site (cervical dystonia: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (cervical dystonia: 4% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Nasopharyngitis (upper limb spasticity: 2%), upper respiratory tract infection (upper limb spasticity: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blepharospasm and glabellar lines:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Xerostomia (blepharospasm: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Blepharoptosis (blepharospasm: 19%; reduction of glabellar lines: &lt;1%), dry eye syndrome (blepharospasm: 16%), visual disturbance (blepharospasm: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (blepharospasm: 7%; reduction of glabellar lines: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea (blepharospasm: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Dyspnea (blepharospasm: 5%), nasopharyngitis (blepharospasm: 5%), respiratory tract infection (blepharospasm: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Any indication: Abdominal distention, abnormal dreams, allergic dermatitis, alopecia, anaphylaxis, antibody development, asthma, blepharospasm, blurred vision, cardiac insufficiency, circulatory shock, corneal perforation, cough, diplopia, dysarthria, edema, erythema, eye disease, eyelid edema, facial pain, facial paresis, fatigue, fixed drug eruption, flu-like symptoms, hematoma at injection site, herpes zoster, hypersensitivity reaction, inflammation at injection site, injection site reaction, lymphadenopathy, madarosis, muscle spasm, myalgia, nausea, pruritus, reduced blinking (leading to corneal ulceration), serum sickness, skin rash, swelling of eye, trismus, urinary incontinence, urticaria, vascular insufficiency, voice disorder, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826173\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to botulinum toxin or any component of the formulation; infection at the proposed injection site(s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Generalized disorders of muscle activity (eg, myasthenia gravis, Lambert-Eaton syndrome)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826174\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur; discontinue therapy immediately with signs/symptoms of hypersensitivity. Immediate medical treatment should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Higher doses, more frequent administration and/or onset of disease at a younger age may result in neutralizing antibody formation and loss of efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported with use of another botulinum toxin product, sometimes in patients with preexisting cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May impair ability to drive and/or operate machinery due to the intended effects of treatment; if loss of strength, muscle weakness, or impaired vision occur, patients should avoid driving or engaging in other hazardous activities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dysphagia: Common when used for cervical dystonia; may occur within hours to weeks and persist for several months after administration. In severe cases, patients may require alternative feeding methods. Risk factors include smaller neck muscle mass and bilateral injections into the sternocleidomastoid muscle. Incidence of dysphagia may be reduced by limiting dose administered into sternocleidomastoid muscle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: Use with caution in patients with bleeding disorders and/or receiving anticoagulation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic toxicity:<b> [US Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection.</b> The risk is likely greatest in children treated for the unapproved use of spasticity. Systemic effects have occurred following use in approved and unapproved uses, including low doses. Use caution in patients with underlying conditions which may predispose them to these symptoms. Immediate medical attention required if respiratory, speech, or swallowing difficulties appear. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases such as myasthenia gravis or Lambert- Eaton syndrome (contraindicated in Canadian labeling) and neuropathic disorders (such as amyotrophic lateral sclerosis). Risk of adverse events including severe dysphagia and respiratory compromise may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Careful testing of corneal sensation, avoidance of lower lid injections to prevent ectropion, and treatment of epithelial defects are necessary. Therapeutic soft contact lenses, application of protective drops or ointment, or covering the affected eye may help. Gentle pressure at injection site may limit bruising of eyelid. Use caution in patients with angle-closure glaucoma. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use extreme caution in patients with pre-existing respiratory disease; treatment of cervical dystonia using botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product contains albumin and may carry a remote risk of virus transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Botulinum products (incobotulinumtoxinA, abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic therapy: Long-term effects of chronic therapy unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site: Use with caution if there is excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826170\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10826171\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Canadian labeling does not recommend use for temporary improvement in appearance of moderate to severe glabellar lines during pregnancy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20629254\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if incobotulinumtoxinA is excreted in breast milk. The US labeling recommends that caution be exercised when administering incobotulinumtoxinA to nursing women. The Canadian labeling does not recommend use in nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827022\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">IncobotulinumtoxinA is a neurotoxin produced from <i>Clostridium botulinum</i> that inhibits acetylcholine release from peripheral cholinergic nerve endings. Inhibition occurs sequentially via binding and internalization of the neurotoxin into presynaptic cholinergic nerve terminals, translocation to the nerve terminal cytosol, and enzymatic cleavage of SNAP25, a protein necessary for acetylcholine release. Inhibition of acetylcholine release at the neuromuscular junction produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10827164\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (improvement): ~4 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~3 to 4 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not expected to be present in peripheral blood at recommended doses following IM injection </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322861\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Xeomin Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 unit (1): $303.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 unit (1): $578.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 unit (1): $1,156.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777392\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Xeomeen (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Xeomin (AR, AT, AU, BB, BG, BR, CH, CU, DE, DK, ES, FI, FR, GB, HK, HU, IE, IS, IT, KR, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Benecke R, Jost WH, Kanovsky P, et al, &ldquo;A New Botulinum Toxin Type A Free of Complexing Proteins for Treatment of Dystonia,&rdquo; <i>Neurology</i>, 2005, 64(11):1949-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/incobotulinumtoxina-xeomin-drug-information/abstract-text/15955951/pubmed\" target=\"_blank\" id=\"15955951\">15955951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jankovic J, &ldquo;Clinical Efficacy and Tolerability of Xeomin in the Treatment of Blepharospasm,&rdquo; <i>Eur J Neurol</i>, 2009, 16 (Suppl 2):14-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/incobotulinumtoxina-xeomin-drug-information/abstract-text/20002742/pubmed\" target=\"_blank\" id=\"20002742\">20002742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xeomin (IncobotulinumtoxinA) [prescribing information] Raleigh, NC: Merz Pharmaceuticals; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xeomin (IncobotulinumtoxinA) [product monograph]. Burlington, Ontario, Canada: Merz Pharma Canada Ltd.; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xeomin Cosmetic (IncobotulinumtoxinA) [product monograph]. Burlington, Ontario, Canada: Merz Pharma Canada Ltd.; July 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15586 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10826166\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10894929\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10826168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10493109\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10827173\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F10827175\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10827171\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10827170\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10894930\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F10826169\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F16124978\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10826167\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10827176\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10493111\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26341089\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10493106\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10826360\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10826173\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10826174\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10826170\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10826171\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20629254\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10827022\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10827164\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322861\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777392\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/15586|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=incobotulinumtoxina-xeomin-patient-drug-information\" class=\"drug drug_patient\">IncobotulinumtoxinA (Xeomin): Patient drug information</a></li></ul></div></div>","javascript":null}